News Category
Helus Pharma's appointments of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board signal strategic preparation ...
Helus Pharma's completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder brings the company closer to a p...
Helus Pharma's appointment of Michael Halstead, a seasoned biopharmaceutical leader, signals strategic preparation for the potential commercialization...
Website Rental Coaching (WRC) founder Luke Van Der Veer announces the global expansion of his local SEO training program to 14 countries, now serving ...
Ireland's new Mental Health Act bans electroconvulsive therapy (ECT) for individuals under 18, marking a significant human rights milestone that advoc...
Helus Pharma reported fiscal 2026 financial results, highlighting over 88% enrollment in its Phase 3 APPROACH trial for HLP003, with topline data expe...
Helus Pharma raised $50 million in a public offering to fund Phase 3 trials for its depression treatment and other pipeline candidates, highlighting i...
The Japan Creator Support Fund progress report reveals tangible international outcomes including awards, nominations, and co-productions across music,...
Helus Pharma announced the pricing of a $50 million public offering to fund Phase 3 trials for its depression treatment HLP003, with topline data expe...
Helus Pharma announced that its Phase 3 APPROACH trial evaluating HLP003 for major depressive disorder has surpassed 86% enrollment and remains on tra...
Helus Pharma's Chief Medical Officer will discuss the company's novel serotonergic agonists in a fireside chat at the H.C. Wainwright Neuro Perspectiv...
Craig Munro Wilson's 'Baptize America' reveals how the 1820 Campbell-Walker debate on baptism defined the frontier's religious identity and continues ...
Helus Pharma issued a correction to its TARA Mind partnership press release, removing references to Veterans Exploring Treatment Solutions while reaff...
Helus Pharma strengthens its Scientific Advisory Board with renowned experts Robert Langer and Stephen Brannan to advance its novel serotonergic agoni...
Helus Pharma announced the immediate resignation of CEO Michael Cola and appointment of Eric So as Interim CEO, aiming to ensure continuity as the com...
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists, has appointed Dr. Ken Kramer as senior vice president of...
The launch of Europe’s first data center operating on a microgrid near Dublin marks a significant milestone in sustainable digital infrastructure, red...
Helus Pharma announced positive Phase 2 topline results for HLP004, showing significant anxiety reduction in GAD patients with limited treatment optio...
Helus Pharma has appointed Dr. Freda Lewis-Hall, a veteran biopharmaceutical leader with over 40 years of experience, to its board and as chair of the...
Helus Pharma announced that a Phase 2a trial of SPL026 met its primary endpoint, showing significant reductions in depressive symptoms, with results p...
Helus Pharma's Q3 2025 results show strong cash position and progress in Phase 3 and Phase 2 trials for major depressive disorder and generalized anxi...
Helus Pharma announced Michael Cola as CEO, signaling a strategic shift toward late-stage development and commercial planning, with pivotal Phase 2 an...
